Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases

1

The study evaluated the vaccine effectiveness of the adjuvanted recombinant zoster vaccine (RZV) in adults aged 50 and older with autoimmune diseases.
2

A total of 36,645 vaccinated and 109,229 unvaccinated patients were analyzed, revealing significant differences in herpes zoster incidence.
3

Vaccine effectiveness against herpes zoster ranged from 48.1% for multiple sclerosis to 77.2% for psoriasis, demonstrating varying efficacy across conditions.
4

Overall, the study found a 66.3% reduction in herpes zoster incidence among vaccinated individuals compared to unvaccinated counterparts.
5

This real-world analysis supports the use of RZV for preventing herpes zoster in older adults with selected autoimmune disorders.

The Journal Of Infectious Diseases

by Dagna Constenla, Germain Lonnet, Emmanuel Aris, Ramsanjay Rk, Nathalie Servotte, Agnes Mwakingwe-Omari, Hannah Alsdurf, Huifeng Yun
August 11, 2025

1